Bionano Genomics (NASDAQ:BNGO) Cut to “Neutral” at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH cut shares of Bionano Genomics (NASDAQ:BNGO) from a buy rating to a neutral rating in a report issued on Friday morning, Marketbeat.com reports.

A number of other brokerages have also weighed in on BNGO. Scotiabank restated a “sector perform” rating and set a $1.00 target price (down previously from $6.00) on shares of Bionano Genomics in a research report on Wednesday, August 28th. BTIG Research downgraded Bionano Genomics from a “buy” rating to a “neutral” rating in a research report on Tuesday, September 10th.

Bionano Genomics Stock Performance

NASDAQ BNGO opened at $0.25 on Friday. The business has a 50-day moving average price of $0.36 and a 200-day moving average price of $0.59. The firm has a market cap of $21.16 million, a price-to-earnings ratio of -0.11 and a beta of 2.37. Bionano Genomics has a twelve month low of $0.24 and a twelve month high of $2.27. The company has a quick ratio of 1.11, a current ratio of 1.63 and a debt-to-equity ratio of 0.04.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new position in shares of Bionano Genomics during the first quarter valued at approximately $36,000. Price T Rowe Associates Inc. MD increased its holdings in shares of Bionano Genomics by 123.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 70,370 shares of the company’s stock valued at $79,000 after acquiring an additional 38,900 shares during the period. Armistice Capital LLC bought a new position in shares of Bionano Genomics in the 2nd quarter worth $1,138,000. Cetera Advisors LLC purchased a new stake in shares of Bionano Genomics during the 1st quarter worth $163,000. Finally, Carret Asset Management LLC boosted its position in Bionano Genomics by 89.0% during the third quarter. Carret Asset Management LLC now owns 85,055 shares of the company’s stock valued at $39,000 after purchasing an additional 40,055 shares in the last quarter. Hedge funds and other institutional investors own 11.35% of the company’s stock.

Bionano Genomics Company Profile

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.